CVS vs PFE: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
PFE is the larger of the two ($168.60B market cap): the incumbent the market prices for continued execution (10.19x forward earnings, beta 0.28). CVS is the smaller challenger ($118.13B), priced similarly on forward earnings (10.82x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
CVS vs PFE: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CVS | PFE | What it tells you |
|---|---|---|---|
| Market cap | $118.13B | $168.60B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 10.82 | 10.19 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 24.31 | 38.92 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.60 | 0.28 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 56% of range | 95% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.48 | 1.98 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how CVS and PFE affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CVS and PFE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CVS and PFE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does CVS Health (CVS) do?
CVS Health runs three reporting segments. Health Care Benefits is the Aetna insurance business, which earns premiums from roughly 26 million medical members and profits when claims (the medical benefit ratio) stay below what it collects. Health Services is built around the Caremark pharmacy benefit manager, which negotiates drug prices and manages pharmacy claims for health plans and employers and generated over $48 billion of revenue in Q1 2026. Pharmacy and Consumer Wellness is the familiar retail footprint of CVS drugstores, which makes money filling prescriptions and selling front-of-store health and consumer goods, with same-store prescription volumes up nearly 7% in Q1 2026.
What does Pfizer (PFE) do?
Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. Its portfolio spans oncology (a strategic priority, expanded sharply by the acquisition of cancer drugmaker Seagen), vaccines (including pneumococcal franchise Prevnar and its COVID-19 vaccine Comirnaty, partnered with BioNTech), internal medicine and cardiology (such as the Vyndaqel/Vyndamax family and Eliquis, co-marketed with Bristol Myers Squibb), immunology and inflammation, and antivirals (including the COVID treatment Paxlovid). Pfizer makes money selling these drugs to wholesalers, pharmacies, hospitals, and governments worldwide. The company saw an enormous revenue surge from COVID-19 products during the pandemic, then a steep decline as that demand normalized, leaving it to refill growth through its pipeline, oncology expansion, and acquisitions while a wave of patent expirations looms later this decade. Founded in 1849 and headquartered in New York City, Pfizer is a mature, dividend-paying large-cap navigating a post-COVID reset.
CVS vs PFE: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- CVS drivers: Integrated model under one roof; Turnaround and improving Aetna margins.
- PFE drivers: Oncology expansion via Seagen; Broad, diversified portfolio.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. For PFE, pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap.
CVS or PFE: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CVS if you believe its drivers more; PFE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CVS and PFE guides.
CVS vs PFE: the full fundamentals
CVS. CVS trades near 11x forward earnings and about 0.3x sales, a low multiple versus the broad market that reflects lingering caution after the 2023 to 2024 Aetna downturn and continuing PBM and legal risk rather than current results, which have beaten estimates four quarters running. Q3 2026 results are scheduled for November 4, 2026, with consensus adjusted EPS near $1.65 on ~$105 billion of revenue. Figures are approximate and tied to the asOf date; verify live quotes and the latest filings before acting.
PFE. Pfizer trades at about 10x forward earnings and a dividend yield near 5.8%, a below-market multiple that reflects investor concern about the post-COVID revenue reset and a looming patent cliff. The gap between a trailing GAAP P/E near 39x and the forward figure comes from large GAAP charges rather than weak operations. Even after a 17.5% gain in 2026 the shares sit right around the 26 analysts' mean target of about $29, so the valuation now balances substantial cash generation against flat-to-lower consensus earnings.
Headline figures (approximate, October 2026): CVS shows revenue (ttm) ~$413 billion (Q2 2026 ~$106B, up ~7% YoY), adjusted eps Q2 2026 $2.58 vs $1.85 estimate; 2026 consensus ~$8.04, 2027 ~$8.54, net income (ttm) ~$4.9 billion (net margin ~1.2%), aetna medical benefit ratio (q1 2026) ~84.6%, improved from ~87.3% a year earlier; PFE shows revenue (ttm) ~$63.7 billion (Q2 2026 +~2.6% YoY), operating margin ~28%, net income (ttm, gaap) ~$4.3 billion, q2 2026 adjusted eps ~$0.77 vs ~$0.68 consensus.
The bottom line: CVS vs PFE
CVS and PFE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CVS and PFE exposure against your real portfolio. It is not an investment adviser.
Wondering how CVS or PFE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in CVS Health with AI
Connect the broker you already use and ask Walnut's AI how CVS fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between CVS and PFE?
+
CVS Health runs three reporting segments. Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CVS or PFE the better stock?
+
Neither is universally better. PFE is the larger incumbent; CVS is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CVS or PFE?
+
On forward P/E (as of October 2026), CVS trades at 10.82x and PFE at 10.19x, so PFE is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CVS and PFE?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CVS vs PFE?
+
CVS: The clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. The Caremark PBM faces intensifying regulatory and political pressure, including FTC litigation, a 2026 House Judiciary antitrust report, state investigations in Florida and elsewhere, and rebate pass-through reform that could compress a core profit pool. Legal costs continue: in October 2026 CVS agreed to a $315 million settlement of federal claims over opioid dispensing, with new controlled-substance oversight measures. The retail pharmacy business faces reimbursement pressure and store closures, and the company carries about $76 billion of debt, much of it from the Aetna deal, which limits flexibility if the turnaround stalls. PFE: Pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap. Analysts' consensus as of October 2026 has revenue slipping to about $62.2 billion in 2026 and $59.9 billion in 2027, with EPS of roughly $2.96 and $2.89, so earnings are expected to drift lower rather than grow. COVID-19 product revenue (Comirnaty, Paxlovid) has fallen sharply and remains volatile and hard to forecast. The Seagen deal added substantial debt (total debt is about $63.5 billion against $11.7 billion of cash), and large acquisitions carry integration and return risk. The dividend exceeds GAAP earnings (a payout above 200% on trailing GAAP EPS), so it leans on adjusted earnings and cash flow. Drug pricing pressure, including US policy such as Medicare negotiation, threatens margins on key products. Pipeline setbacks, clinical-trial failures, and regulatory decisions can swing the stock, and the company must continually prove it can generate new blockbusters to sustain growth as legacy drugs mature.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CVS or PFE; figures are approximate and dated (as of October 2026). Verify current data before investing.